Since PI3K-δ is preferentially expressed in leukocytes, may be particularly active in hematological malignancies; furthermore, the targeted inhibition of PI3K-δ is designed to preserve PI3K signaling in normal cells. The gene discussed is PIK3CA; the disease is hematologic disorder.